Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning

Yuen, Sze Chung; Liang, Xueya; Zhu, Hongmei; Jia, Yongliang; Leung, Siu-wai

doi:10.1186/s13195-021-00862-z

Cited by 36 publications

(19 citation statements)

References 219 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs were a phenomenon discovered in 1993, and ever since, there has been much interest in their ability to regulate gene expression within diseases [ 30 ]. More recently, they have been studied as biomarker candidates of many pathologies, including AD, in blood and CSF [ 31 , 32 ]. A comparison between blood/CSF miRNAs and brain DE-miRNAs of this research is available in (Supplementary Materials Table S3) .…”

Section: Discussionmentioning

confidence: 99%

Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients

Watson

Begum

Ashman

et al. 2022

Cells

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia globally; however, the aetiology of AD remains elusive hindering the development of effective therapeutics. MicroRNAs (miRNAs) are regulators of gene expression and have been of growing interest in recent studies in many pathologies including AD not only for their use as biomarkers but also for their implications in the therapeutic field. In this study, miRNA and protein profiles were obtained from brain tissues of different stage (Braak III-IV and Braak V-VI) of AD patients and compared to matched controls. The aim of the study was to identify in the late stage of AD, the key dysregulated pathways that may contribute to pathogenesis and then to evaluate whether any of these pathways could be detected in the early phase of AD, opening new opportunity for early treatment that could stop or delay the pathology. Six common pathways were found regulated by miRNAs and proteins in the late stage of AD, with one of them (Rap1 signalling) activated since the early phase. MiRNAs and proteins were also compared to explore an inverse trend of expression which could lead to the identification of new therapeutic targets. These results suggest that specific miRNA changes could represent molecular fingerprint of neurodegenerative processes and potential therapeutic targets for early intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients

Watson

Begum

Ashman

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…Recent efforts from meta-analyses that aim to identify circulating miRNAs for AD detection have and will further increase our understanding of miRNAs as liquid biopsy markers in AD. [102][103][104] Therefore, the aforementioned meta-analyses and the propositions of biofluid panels for the detection of AD may allow liquid biopsy establishment in AD diagnosis.…”

Section: Mirnasmentioning

confidence: 99%

Nucleic Acid Liquid Biopsies in Alzheimer’s Disease: Current State, Challenges, and Opportunities

Soelter¹,

Whitlock²,

Williams³

et al. 2022

Preprint

View full text Add to dashboard Cite

Alzheimer’s disease is the most common neurodegenerative disease and affects persons of all races, ethnic groups, and sexes. The disease is characterized by neuronal loss leading to cognitive decline and memory loss. There is no cure and the effectiveness of existing treatments is limited and depends on the time of diagnosis. The long prodromal period, during which patients’ ability to live a normal life is not affected despite neuronal loss, often leads to a delayed diagnosis because it can be mistaken for normal aging of the brain. In order to make a substantial impact on AD patients, early diagnosis may provide a greater therapeutic window for future therapies to slow AD-associated neurodegeneration. Current gold standards for disease detection include magnetic resonance imaging and positron emission tomography scans, which visualize amyloid β and phosphorylated tau depositions and aggregates. Liquid biopsies, already an active field of research in precision oncology, are hypothesized to provide early disease detection through minimally or non-invasive sample collection techniques. Liquid biopsies in Alzheimer’s disease have been studied in cerebrospinal fluid, blood, ocular, oral, and olfactory fluids. However, most of the focus has been on blood and cerebrospinal fluid due to biomarker specificity and sensitivity attributed to the effects of the blood-brain barrier and inter-laboratory variation during sample collection. Many studies have identified amyloid β and phosphorylated tau levels as putative biomarkers, however, advances in next-generation sequencing-based liquid biopsy methods have led to significant interest in identifying nucleic acids species associated with Alzheimer’s disease from liquid tissues. Differences in cell-free RNAs and DNAs have been described as potential biomarkers for AD and hold the potential to affect disease diagnosis, treatment, and future research avenues.

show abstract

“…miRNAs are small, non-coding RNAs that help regulate gene expression by silencing or activating mRNA transcripts (O'Brien et al, 2018). While there is an extensive evidence demonstrating the mechanistic action of miRNAs in exacerbating obese phenotype (McGregor and Choi, 2011;Mentzel et al, 2015;Iacomino and Siani, 2017), as well as recent evidence in literature demonstrating the role of circulating levels of miRNAs in neurodegenerative disease (Sharma and Lu, 2018;Salama et al, 2019;Yuen et al, 2021). However, there have been limited research that links the underlying mechanisms operant with transcriptional regulation of miRNAs in cognitive decline and neurodegeneration caused by obesity and associated comorbidities.…”

Section: Deckers Et Al 2017mentioning

confidence: 99%

A Review of miRNAs as Biomarkers and Effect of Dietary Modulation in Obesity Associated Cognitive Decline and Neurodegenerative Disorders

Perdoncin

Konrad

Wyner

et al. 2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

There has been a progressive increase in the prevalence of obesity and its comorbidities such as type 2 diabetes and cardiovascular diseases worldwide. Recent studies have suggested that the crosstalk between adipose tissue and central nervous system (CNS), through cellular mediators and signaling pathways, may causally link obesity with cognitive decline and give rise to neurodegenerative disorders. Several mechanisms have been proposed in obesity, including inflammation, oxidative stress, insulin resistance, altered lipid and cholesterol homeostasis, which may result in neuroinflammation, altered brain insulin signaling, amyloid-beta (Aβ) deposition and neuronal cell death. Since obesity is associated with functional and morphological alterations in the adipose tissues, the resulting peripheral immune response augments the development and progression of cognitive decline and increases susceptibility of neurodegenerative disorders, such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Studies have also elucidated an important role of high fat diet in the exacerbation of these clinical conditions. However, the underlying factors that propel and sustain this obesity associated cognitive decline and neurodegeneration, remains highly elusive. Moreover, the mechanisms linking these phenomena are not well-understood. The cumulative line of evidence have demonstrated an important role of microRNAs (miRNAs), a class of small non-coding RNAs that regulate gene expression and transcriptional changes, as biomarkers of pathophysiological conditions. Despite the lack of utility in current clinical practices, miRNAs have been shown to be highly specific and sensitive to the clinical condition being studied. Based on these observations, this review aims to assess the role of several miRNAs and aim to elucidate underlying mechanisms that link obesity with cognitive decline and neurodegenerative disorders. Furthermore, this review will also provide evidence for the effect of dietary modulation which can potentially ameliorate cognitive decline and neurodegenerative diseases associated with obesity.

show abstract

Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning

Cited by 36 publications

References 219 publications

Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients

Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients

Nucleic Acid Liquid Biopsies in Alzheimer’s Disease: Current State, Challenges, and Opportunities

A Review of miRNAs as Biomarkers and Effect of Dietary Modulation in Obesity Associated Cognitive Decline and Neurodegenerative Disorders

Contact Info

Product

Resources

About